2. Anti-infection Vitamin D Related/Nuclear Receptor Membrane Transporter/Ion Channel
  3. Bacterial Estrogen Receptor/ERR FATP
  4. (Z)-Ligustilide

(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.

For research use only. We do not sell to patients.

(Z)-Ligustilide Chemical Structure

(Z)-Ligustilide Chemical Structure

CAS No. : 81944-09-4

Size Price Stock Quantity
5 mg USD 50 In-stock
10 mg USD 90 In-stock
20 mg USD 150 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of (Z)-Ligustilide:

(Z)-Ligustilide Related Antibodies

Top Publications Citing Use of Products

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6[1]. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) [2]. (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer[3].

IC50 & Target

ERα

 

In Vitro

Z-ligustilide (25 and 100 µM, 24 hours) can effectively inhibit oleic acid-induced lipid accumulation in HepG2 cells, suppress fatty acid uptake and esterification, and has potential anti-fatty liver effects[2].
Z-ligustilide (10-50 μM, 72 hours) can significantly enhance the sensitivity of ERα-negative breast cancer cells to Tamoxifen (HY-13757A) by restoring the expression of ERα[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(Z)-Ligustilide Related Antibodies

Real Time qPCR[2]

Cell Line: HepG2 cells
Concentration: 25 and 100 µM
Incubation Time: 24 h
Result: Dose-dependently reduced the mRNA expression of FATP5 and DGAT2 genes.

Western Blot Analysis[2]

Cell Line: HepG2 cells
Concentration: 25 and 100 µM
Incubation Time: 24 h
Result: Significantly reduced the expression level of DGAT2 protein.

Cell Cycle Analysis[3]

Cell Line: MDA-MB-231、MDA-MB-453、HS578t cells
Concentration: 10, 25, 50 μM
Incubation Time: 72 h
Result: After co-administration with Tamoxifen (HY-13757A), significantly inhibited cell proliferation, promoted cell apoptosis, and induced cell cycle arrest in the S phase and G2/M phase.
In Vivo

Z-ligustilide (50 mg/kg, p.o., once daily for 6 weeks) significantly reduces hepatic lipid accumulation in high-fat diet-induced fatty liver mice, inhibiting fatty acid uptake and esterification, demonstrating potential application value for non-alcoholic fatty liver disease (NAFLD)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: High-fat diet (HFD)-induced fatty liver model in male C57BL/6 mice[2]
Dosage: 50 mg/kg
Administration: Oral gavage (p.o.), once daily for 6 weeks
Result: Significantly reduced high-fat diet (HFD)-induced hepatic fat accumulation in mice, as confirmed by hepatic TG assay, H&E staining, and Oil Red O staining, showing a marked decrease in liver lipid content.
Significantly inhibited the expression of fatty acid uptake-related genes CD36 and DGAT2, and reduced the expression of SREBP1c and its downstream target genes FAS and SCD1, thereby decreasing lipid production in the liver.
Molecular Weight

190.24

Formula

C12H14O2
CAS No.
Appearance

Liquid (Density: 1.10±0.1 g/cm3)

Color

Colorless to light yellow

SMILES

O=C1O/C(C2=C1C=CCC2)=C\CCC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (525.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.2565 mL 26.2826 mL 52.5652 mL
5 mM 1.0513 mL 5.2565 mL 10.5130 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.11%

SDS (420 KB)

COA (265 KB) HNMR (243 KB) RP-HPLC (210 KB) MS (86 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 5.2565 mL 26.2826 mL 52.5652 mL 131.4129 mL
5 mM 1.0513 mL 5.2565 mL 10.5130 mL 26.2826 mL
10 mM 0.5257 mL 2.6283 mL 5.2565 mL 13.1413 mL
15 mM 0.3504 mL 1.7522 mL 3.5043 mL 8.7609 mL
20 mM 0.2628 mL 1.3141 mL 2.6283 mL 6.5706 mL
25 mM 0.2103 mL 1.0513 mL 2.1026 mL 5.2565 mL
30 mM 0.1752 mL 0.8761 mL 1.7522 mL 4.3804 mL
40 mM 0.1314 mL 0.6571 mL 1.3141 mL 3.2853 mL
50 mM 0.1051 mL 0.5257 mL 1.0513 mL 2.6283 mL
60 mM 0.0876 mL 0.4380 mL 0.8761 mL 2.1902 mL
80 mM 0.0657 mL 0.3285 mL 0.6571 mL 1.6427 mL
100 mM 0.0526 mL 0.2628 mL 0.5257 mL 1.3141 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(Z)-Ligustilide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Z)-Ligustilide81944-09-4BacterialEstrogen Receptor/ERRFATPFatty acid transport proteinNon-alcoholic fatty liver diseaseHepG2 cells High-fat diet (HFD)-induced fatty liver modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(Z)-Ligustilide
Cat. No.:
HY-N0401A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (420 KB) Français - FR (420 KB) Deutsch - DE (420 KB) Norwegian - NO (420 KB) Español - ES (420 KB) Swedish - SV (420 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.